EASY-Diabetes
Financiado
Individualised and Equitable Care of Type 2 Diabetes
EASY – Diabetes is a digital health solution that helps patients with Type 2 diabetes and health care providers analyse data
and make better decisions about therapies by accessing a carefully curated global database based on clini...
EASY – Diabetes is a digital health solution that helps patients with Type 2 diabetes and health care providers analyse data
and make better decisions about therapies by accessing a carefully curated global database based on clinical data and
medical evidence collected over the course of nine years and powered by machine learning algorithms and other forms of
artificial intelligence. We offer EASY-Diabetes as a Software-as-a-Service to healthcare providers at a fee of €50 per patient
per year.
Diabetes is a prevalent and costly chronic disease, affecting 425 million people worldwide. Although 9.2% of the health care
budget in Europe spent on diabetes, the results for patients remain inadequate even in the most advanced healthcare
systems. Patients lack a patient-centred and personalised approach to disease management. 90% of patients with T2D are
treated by GPs in primary care. Most clinics lack both the manpower and the expertise required to deal with the needs of
patients for regular contact with health care providers and the complexity of diabetes treatment. Existing eHealth solutions
show some crucial drawbacks, such as lack of clinical validation against the standard of care, no personalised medical
treatment options, not being drug agnostic.
Our team brings together demonstrated expertise in medicine, clinical trials, drug development, regulatory affairs, product
development, programming, machine learning, business development.
The SME Phase 1 Feasibility study will aim to complete the validation of the commercial feasibility of Easy – Diabetes with
target market segments and key stakeholders. We will strengthen our financial planning and IP protection strategy
necessary to improve our service and refine our go-to-market strategy.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2019-10-23
Fecha Fin: 2020-02-29
Fecha Fin: 2020-02-29
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-02-29
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
ADJUVIA AB
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
350.00K€ |
Participante